Bempegaldesleukin/Nivolumab and Challenges in First-line Treatment of Metastatic Urothelial Carcinoma

Eur Urol. 2022 Oct;82(4):374-376. doi: 10.1016/j.eururo.2022.05.023. Epub 2022 Jun 23.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Carcinoma, Transitional Cell* / drug therapy
  • Carcinoma, Transitional Cell* / pathology
  • Humans
  • Interleukin-2
  • Nivolumab / therapeutic use
  • Urinary Bladder Neoplasms* / drug therapy
  • Urinary Bladder Neoplasms* / pathology
  • Urologic Neoplasms* / drug therapy
  • Urologic Neoplasms* / pathology

Substances

  • Interleukin-2
  • Nivolumab